Comparative Study of Four Antacids M

Total Page:16

File Type:pdf, Size:1020Kb

Comparative Study of Four Antacids M Postgrad Med J: first published as 10.1136/pgmj.60.707.592 on 1 September 1984. Downloaded from Postgraduate Medical Journal (September 1984) 60, 592-596 Comparative study of four antacids M. R. JACYNA E. J. S. BOYD M.B., Ch.B. M.R.C.P. K. G. WORMSLEY M.D., F.R.C.P. Department of Therapeutics, University of Dundee, Dundee capacities. We also considered the cost of each Summary preparation. Four antacid preparations have been studied in a stratified, randomized, double-blind trial to evaluate Methods criteria which determine patients' acceptance of this type of therapy. There was a considerable range of Sixty consecutive patients (36 males and 24 fe- judgements about palatability, but preference was males; mean age 48 years (range 21-76 years)) were determined not only by factors such as the smell, recruited as volunteers from a gastroenterological taste, texture and after-taste of the preparation, but out-patient clinic. The patients suffered from peptic diseases, including duodenal or gastric ulcer and also by the order in which the antacids were tested by copyright. and by the age and sex of the patient. The prepara- oesophagitis. tions also differed considerably in acid-neutralizing capacity and ability to bind bile salts, as well as cost. TABLE 1. Antacids and ingredients We conclude that individuals requiring antacid ther- apy should be allowed to chose from among a range of Code Name Manufacturer Contents preparations, in order to maximize compliance. A Malinal A. H. Robins Almasilate (aluminium magnesium KEY WORDS: oesophagitis, duodenal ulcer, gastric ulcer. silicate) B Asilone Berk Dimethicone Introduction Aluminium hydroxide Magnesium oxide http://pmj.bmj.com/ With the advent and therapeutic efficacy of potent C Gaviscon Reckitt & Sodium bicarbonate inhibitors of gastric secretion, the role of antacids in Colman Sodium alginate the treatment of peptic ulcers has become less D Maalox Rorer Aluminium hydroxide important (Morris and Rhodes, 1979; Editorial, Magnesium hydroxide 1981). However, antacids remain very useful for treating oesophagitis and less well-defined causes of dyspepsia (De Carlo, 1978; Graham, Smith and The 4 antacids studied (Table 1) were placed in identical plain bottles and C Patterson, 1983). The choice of antacids is wide-the labelled A, B, and D. on September 26, 2021 by guest. Protected British National Formulary lists 33 different prepara- The identity of the preparations was not known by tions. The present study was undertaken in order to either investigator or patient. Ten millilitres of each define some criteria for the selection of antacids, by antacid were presented to each individual in a comparing 4 commonly used preparations which balanced, randomized order to ensure that each represent the range ofeffects considered desirable for antacid was evaluated first on 15 occasions. Subjects the treatment of oesophagitis. In a randomized, performed the assessment in a manner analogous to double-blind study, we tested aspects of the accepta- wine-tasting and were asked to 'sniff, sip and savour' bility of the antacids to the patients, and measured the preparation and subsequently to gargle, without the in vitro acid-neutralizing and bile salt-binding swallowing. Following expectoration of the antacid,' patients were asked to grade each of four Correspondence: Dr K. G. Wormsley, NinewelUs Hospital, Dun- criteria-aroma, flavour, texture and after-taste-as dee DD1 9SY, Scotland. 'pleasant', 'acceptable', or 'unpleasant' and then to Postgrad Med J: first published as 10.1136/pgmj.60.707.592 on 1 September 1984. Downloaded from Comparative study offour antacids 593 rank the preparations in order of preference for each these proportions were not significantly different criterion, with the most popular preparation being from the other antacids. given a value of 4 and the least popular a value of 1. When scores for all four criteria were pooled to After each preparation had been tested and assessed, produce an index ofoverall palatability, there was no the mouth was rinsed with warm water until there difference in results from antacids A, B and D. About was no residual taste and the procedure was repeated one-quarter of the patients considered each to be with each one of the other three preparations. 'unpleasant'. Nearly half the patients concluded that Sums of individual judgements for each criterion the overall palatability ofantacid C was 'unpleasant', were used to determine overall palatablity. To a proportion which was significantly higher than for determine overall order of preference, scores for each the other three antacids (P<0.01). criterion were summed. Statistical comparisons were made on absolute numbers using the x2 test. Rank Preference (Table 2) correlation was assessed using the Wilcoxon and Mann-Whitney 'U-tests. A P value of <0-05 was Antacid B was the preferred preparation for three taken as being statistically significant. criteria, including taste (P=n.s.), texture (P<0-02) To determine whether there were any specific age- and after-taste (P<0-02). Antacid C was the least or sex-related differences in patients' acceptance or popular for these criteria (P<0-01 for taste and preference for antacids, the patients were subdivided texture). for the purpose of analysis into four groups: males When preference scores for each ofthe four criteria older or younger than 50 years (n = 17 and 19, were pooled, antacid B was preferred to antacids A respectively) and females subdivided similarly (n = 12 and D (which were ranked equally). Antacid C was in each group). considered to be significantly less pleasant than the Acid-neutralizing capacity was measured by the other three antacids (P<0-01). method of Fordtran, Morawski and Richardson (1973). Bile salt-binding capacity was measured by TABLE 2. Order of preference of antacid prepara- adding 0 33 ml of antacid to 5 ml of a solution of tions by copyright. sodium taurocholate (10 mmol/litre). The pH was Aroma A D C B adjusted to 4 0 with 0-1 mol/litre hydrochloric acid. Taste B: D: A > C The suspension and control tubes (containing sodium Texture B > D: A >> C taurocholate without antacid) were incubated at 37°C Aftertaste B > A: D: C for 60 min and then centrifuged. The bile salt All-round concentration in the supernatant was determined palatability B > A: D >> C with 3-alpha-hydroxy-steroid dehydrogenase in kit :Difference not statistically significant. form (Sterognost-3alpha-Pho; Nyegaard and Co., > Difference significant P<O02. Oslo, Norway) and spectrophotometry. > Difference significant P<0-01. The cost of equivalent amounts of each prepara- http://pmj.bmj.com/ tion was derived from MIMS (Monthly Index of Order of sampling Medical Specialities, July 1983) or, when not avail- Comparison of the palatability scores when each able, from the manufacturer. antacid was tasted first or last showed that for all preparations, all criteria were considered more pleas- ant when the preparation was sampled first than Results when sampled last. The proportion of 'pleasant' judgements was about twice as great when antacids Palatability (Fig. 1) on September 26, 2021 by guest. Protected were tasted first than when tasted last (P<0-01). The There were no differences among the four antacids proportion of 'unpleasant' judgements on tasting last regarding aroma. Two-thirds of the patients consi- did not increase significantly for antacids A, B and D dered this to be 'pleasant' or 'acceptable' for each of but there was a marked increase in the conclusion of the four preparations. There was greater variation 'unpleasant' for antacid C (P<0-01). among the antacids from the point of view of taste, Order of sampling also affected the order of texture and after-taste. More than half the patients preference of each of the preparations. This effect considered that antacid C had an 'unpleasant' taste was so marked that antacids tasted first were invari- and texture, a proportion that was significantly ably ranked first in order of overall preference. higher than for preparations A, B and D (P<0.01). The majority of patients (82%) considered prepara- tion D to be 'pleasant' or 'acceptable' to taste, while Age- and sex-related differences in judgement antacid B was considered by almost all patients (9 1%) There was no significant difference between the to have a 'pleasant' or 'acceptable' after-taste, but different age and sex groups for order of preference Postgrad Med J: first published as 10.1136/pgmj.60.707.592 on 1 September 1984. Downloaded from 594 M. R. Jacyna, E. J. S. Boyd and K. G. Wormsley for the antacids. However, there were differences less than 50 years old. The latter, however, preferred between groups in their judgement of palatability. the smell, taste and after-taste of antacid C signifi- Males over the age of 50 were more likely to give cantly more than men older than 50 (P<0-02). antacid D a rating of 'pleasant' or 'acceptable' than other groups (P<001). Males (of all ages) gave Acid-neutralizing capacity antacid C more 'unpleasant' ratings than did females (P<0 05). The antacids showed a 4-fold range of buffering Among age-related differences, we noted that capacity, so that 10 ml of antacid buffered from 96 to patients under the age of 50 years (male and female) 350 ml gastic juice containing 100 mmol/litre of were more likely to regard antacid B as being hydrochloric acid (Table 3). pleasant than were patients older than 50 (P<0-02), while male patients older than 50 considered antacid Bile acid-binding capacity A to taste significantly better (P<0-02) than women The four preparations were all reasonably potent 100 100 100 100- 25~~~2 804 ......20'~~ ~2~~80842..... 2 60 43 50 26 38 60 ~~~~~~841 48 4 60 43A B 60 C D 61 A B 600C D A B C: D by copyright.
Recommended publications
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Package Leaflet: Information for the Patient Megalac Almasilate 1 G/10
    Package leaflet: Information for the patient Megalac® Almasilate 1 g/10 mL suspension Active substance: almasilate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse. What is in this leaflet 1. What Megalac® Almasilate is and what it is used for 2. What you need to know before you take Megalac® Almasilate 3. How to take Megalac® Almasilate 4. Possible side effects 5. How to store Megalac® Almasilate 6. Contents of the pack and other information 1. What Megalac® Almasilate is and what it is used for Megalac® Almasilate is a medicine that neutralises excess stomach acid (antacid). Megalac® Almasilate is used for the symptomatic treatment of diseases where it is required to neutralise acid in the stomach: - stomach and duodenal ulcers - heartburn and stomach problems caused by excess stomach acid 2. What you need to know before you take Megalac® Almasilate Do not take Megalac® Almasilate - if you are allergic to almasilate or any of the other ingredients of this medicine (listed in section 6.), - if your blood phosphate levels are low (hypophosphataemia).
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]